Trial Outcomes & Findings for Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities (NCT NCT00054756)

NCT ID: NCT00054756

Last Updated: 2018-08-08

Results Overview

Serum TSH Levels in Response to TRH Administration

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

96 participants

Primary outcome timeframe

180 minutes from infusion

Results posted on

2018-08-08

Participant Flow

Participant milestones

Participant milestones
Measure
Thyrotropin Releasing Hormone
Subjects receiving TRH (Thyrotropin Releasing Hormone)
Overall Study
STARTED
96
Overall Study
COMPLETED
94
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Two participants did not report sex.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Thyrotropin Releasing Hormone
n=96 Participants
Subjects receiving TRH (Thyrotropin Releasing Hormone)
Age, Categorical
<=18 years
2 Participants
n=96 Participants
Age, Categorical
Between 18 and 65 years
92 Participants
n=96 Participants
Age, Categorical
>=65 years
2 Participants
n=96 Participants
Age, Continuous
38 years
n=96 Participants
Sex: Female, Male
Female
58 Participants
n=94 Participants • Two participants did not report sex.
Sex: Female, Male
Male
36 Participants
n=94 Participants • Two participants did not report sex.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=96 Participants
Race (NIH/OMB)
Asian
2 Participants
n=96 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=96 Participants
Race (NIH/OMB)
Black or African American
19 Participants
n=96 Participants
Race (NIH/OMB)
White
68 Participants
n=96 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=96 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
n=96 Participants

PRIMARY outcome

Timeframe: 180 minutes from infusion

Population: 2 participants did not have results drawn at 180 minutes

Serum TSH Levels in Response to TRH Administration

Outcome measures

Outcome measures
Measure
Thyrotropin Releasing Hormone
n=94 Participants
Subjects receiving TRH (Thyrotropin Releasing Hormone)
TSH Response to TRH
11.47 mcIU/mL
Interval 0.01 to 233.0

Adverse Events

Thyrotropin Releasing Hormone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Joanna Klubo-Gwiezdzinska

NIDDK

Phone: 301-496-1211

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place